Renovo is spin-off of the Cleveland Clinic, and a CRO that specializes in preclinical research.
At Renovo, our vision is “Innovations in Translational Research”
Renovo is a diverse growing company committed to quality innovative solutions for our clients. Our mission is to provide high-quality preclinical proof-of-concept (POC) research services specializing in neuroscience. Our core expertise includes preclinical POC testing for neurodegenerative diseases, in vitro and in vivo assays, neurohistology services and 3-dimensional electron microscopy imaging and analysis. We strive to provide high quality translational research services to clients, including biotech and pharmaceutical companies, research organizations and academic researchers by complementing their in-house capabilities. Currently Renovo provides a comprehensive package for early stage drug development of Multiple Sclerosis therapies and continues to develop niche services to build its portfolio to serve other neurodegenerative diseases.
Renovo’s core scientific strength and expertise supports reliable and reproducible preclinical assays/models. Renovo provides services on a strictly fee-for-service basis with no stake in intellectual property rights on the work performed for its clients. A comprehensive report is submitted to clients at the end of each project.
Renovo was established in 2008 based on the technology developed in the laboratories of Dr. Bruce Trapp and Dr. Wendy Macklin at the Cleveland Clinic. A strong team of research scientists (Doctoral, Masters and Bachelors levels) trained in neuroscience form the core of Renovo’s technical expertise. Renovo operates in a state-of-the-art laboratory with access to nearby Cleveland Clinic Foundation facilities and infrastructure.